FDA halts use of REGEN-COV, Eli Lilly monoclonal antibodies
By
Alicia Lasek
Jan 26, 2022
The Food and Drug Administration has revoked its emergency use authorizations for two monoclonal antibody cocktails that have served as COVID-19 treatment mainstays in long-term care facilities.
Regeneron says its antibody cocktail likely weakened by omicron variant
Nov 30, 2021
No direct data yet available testing the new variant’s resistance to immunity from monoclonal antibodies and vaccines
Clinical briefs for Wednesday, Dec. 1
By
Alicia Lasek
Dec 01, 2021
Regeneron’s COVID-19 antibody drug may be less effective against omicron, drugmaker says … Pandemic taking toll on healthcare workers’ sleep patterns … Ambulance staffing shortage frustrating nursing...
One shot of REGEN-COV prevents COVID infection for 8 months, clinical trial finds
By
Alicia Lasek
Nov 09, 2021
A single dose delivered by subcutaneous injection cut the 8-month risk of contracting COVID-19 by 82% — nearly the same rate of protection found at one month, the company announced Monday.
Clinical briefs for Friday, Oct 1
By
Alicia Lasek
Oct 01, 2021
REGEN-COV antibody treatment cuts severe COVID risk at half dose, late-stage trial results show … Drug improves memory and function for those with dementia and ‘silent seizures’ … Depression relapse...
COVID-19 antiviral drug trials expected to wrap up within months: report
By
Alicia Lasek
Sep 27, 2021
Clinical trials for new COVID-19 antiviral drugs are expected to wrap up by winter, sparking hopes that a daily pill to treat COVID-19 infection is closer to fruition, according to a new report.
Antibody shot cuts COVID-19 infection risk by 66 percent after exposure, drugmaker says
By
Alicia Lasek
Aug 09, 2021
Regeneron’s REGEN-COV antibody cocktail significantly reduces the relative risk of infection after exposure to a close contact infected with SARS-CoV-2, new data show. Symptomatic illness is also shorter...
Feds approve Regeneron’s antibody therapy as COVID-19 preventive
By
Alicia Lasek
Aug 03, 2021
REGEN-COV now can be used after exposure to the SARS-CoV-2 virus to prevent severe illness in people at high risk of poor outcomes from COVID-19.
A first: Regeneron’s antibody cocktail cuts mortality by 20 percent in severe COVID
By
Alicia Lasek
Jun 17, 2021
The results are promising for vulnerable COVID-19 patients who can’t mount their own immune response to the disease, the study revealed. The findings also may ease uncertainty about the value of...
FDA allows injections, reduced dose of COVID monoclonal antibody therapy
By
Alicia Lasek
Jun 08, 2021
An effective but arguably underused COVID-19 monoclonal antibody therapy now may be more accessible for long-term care facilities that aren’t equipped to deliver intravenous infusions.